CD274 and neoplasm: A recent study indicated that EVs released from TNBC cells that were bioengineered to express a high–affinity variant of the human PD–1 protein (havPD–1) and knockdown intrinsic PD–L1 and β2–microglobulin reduce tumor proliferation and promote apoptosis via the downregulation of PD–L1–dependent T–cell suppression [152].